Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses

  • Matthew Herper

By Matthew Herper Sept. 16, 2020

Reprints
Francis deSouza
Francis deSouza, president and chief executive officer of Illumina Jeff Spicer/PA Wire via AP

Illumina, the dominant maker of machines to sequence DNA, is in talks to purchase Grail, a developer of a blood test to detect cancer that uses Illumina’s technology.

The discussions were first reported by Bloomberg News, and confirmed to STAT by a person with knowledge of the talks. The discussions could still fall apart at any time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Oscar Health names former Aetna executive as new CEO
Oscar Health names former Aetna executive as new CEO
Pharmalittle: Ohio attorney general accuses PBMs of price fixing;…
Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price…
With new study data, Intra-Cellular could expand use of…
With new study data, Intra-Cellular could expand use of approved mood-disorder treatment

Comments are closed.

Recommended Stories